✦ LIBER ✦

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group

✍ Scribed by Jill Gilbert; Ju Whei Lee; Athanassios Argiris; Missak Haigentz Jr.; Lawrence Eric Feldman; Minyoung Jang; Pattatheyil Arun; Carter Van Waes; Arlene A. Forastiere

Book ID: 112097774
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 776 KB
Volume: 35
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.23046

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr